These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26626277)

  • 21. HIV-1 Genetic Diversity and Natural Polymorphisms of the Integrase Gene in Integrase Inhibitor-Naive Patients in Harare, Zimbabwe.
    Madyadi A; Dhoro M; Shamu T; Washaya T; Kouamou V; Chimukangara B; Katzenstein D; Manasa J
    AIDS Res Hum Retroviruses; 2021 Dec; 37(12):954-961. PubMed ID: 34714124
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
    Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M
    J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.
    Garrido C; de Mendoza C; Alvarez E; García F; Morello J; Garcia S; Ribera E; Rodríguez-Novoa S; Gutierrez F; Soriano V;
    AIDS Res Hum Retroviruses; 2012 Feb; 28(2):156-64. PubMed ID: 21457126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of HIV-1 integrase genotypes and polymorphisms among integrase inhibitors-based antiretroviral treatment naïve patients in South Sudan.
    Giovanetti M; Farcomeni S; Sernicola L; Virtuoso S; Fontanelli Sulekova L; Maggiorella MT; Buttò S; Taliani G; Ciccozzi M; Borsetti A
    J Med Virol; 2022 Jul; 94(7):3320-3327. PubMed ID: 35277871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
    Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
    J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
    Goethals O; Vos A; Van Ginderen M; Geluykens P; Smits V; Schols D; Hertogs K; Clayton R
    Virology; 2010 Jul; 402(2):338-46. PubMed ID: 20421122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance-Associated Mutations and Polymorphisms among Integrase Inhibitor-Naïve HIV-1 Patients in Kuwait.
    Chehadeh W; Albaksami O; John SE; Al-Nakib W
    Intervirology; 2017; 60(4):131-137. PubMed ID: 29212076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.
    Garrido C; Soriano V; Geretti AM; Zahonero N; Garcia S; Booth C; Gutierrez F; Viciana I; de Mendoza C
    Antiviral Res; 2011 Jun; 90(3):164-7. PubMed ID: 21439330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients.
    Sayan M; Gündüz A; Ersöz G; İnan A; Deveci A; Özgür G; Sargın F; Karagöz G; İnci A; İnan D; Ülçay A; Karaoğlan I; Kaya S; Kutlu SS; Süer K; Çağatay A; Akalın H
    HIV Clin Trials; 2016 May; 17(3):109-13. PubMed ID: 27125365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short Communication: Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals.
    López P; Tirado G; Arias A; Sánchez R; Rodríguez-López ER; Rivera-Amill V
    Int J Environ Res Public Health; 2021 Mar; 18(5):. PubMed ID: 33800269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent inhibitors of HIV-1 integrase display a two-step, slow-binding inhibition mechanism which is absent in a drug-resistant T66I/M154I mutant.
    Garvey EP; Schwartz B; Gartland MJ; Lang S; Halsey W; Sathe G; Carter HL; Weaver KL
    Biochemistry; 2009 Feb; 48(7):1644-53. PubMed ID: 19178153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discordant predictions of residual activity could impact dolutegravir prescription upon raltegravir failure.
    Theys K; Abecasis A; Libin P; Gomes PT; Cabanas J; Camacho RJ; Van Laethem K
    J Clin Virol; 2015 Sep; 70():120-127. PubMed ID: 26305833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of drug resistance-associated mutations in treatment-naïve individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union.
    Vázquez de Parga E; Rakhmanova A; Pérez-Alvarez L; Vinogradova A; Delgado E; Thomson MM; Casado G; Sierra M; Muñoz M; Carmona R; Vega Y; Contreras G; Medrano L; Osmanov S; Nájera R
    J Med Virol; 2005 Nov; 77(3):337-44. PubMed ID: 16173024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV type 1 integrase polymorphisms in treatment-naive and treatment-experienced HIV type 1-infected patients in Thailand where HIV type 1 subtype A/E predominates.
    Phuphuakrat A; Pasomsub E; Kiertiburanakul S; Chantratita W; Sungkanuparph S
    AIDS Res Hum Retroviruses; 2012 Aug; 28(8):937-43. PubMed ID: 21970343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.
    El Bouzidi K; Kemp SA; Datir RP; Murtala-Ibrahim F; Aliyu A; Kwaghe V; Frampton D; Roy S; Breuer J; Sabin CA; Ogbanufe O; Charurat ME; Bonsall D; Golubchik T; Fraser C; Dakum P; Ndembi N; Gupta RK
    J Antimicrob Chemother; 2020 Jun; 75(6):1575-1579. PubMed ID: 32105319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.
    Alidjinou EK; Deldalle J; Hallaert C; Robineau O; Ajana F; Choisy P; Hober D; Bocket L
    J Antimicrob Chemother; 2017 Oct; 72(10):2823-2830. PubMed ID: 29091197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of genotypic diversity on selection of subtype-specific drug resistance profiles during raltegravir-based therapy in individuals infected with B and BF recombinant HIV-1 strains.
    Sánchez D; Arazi Caillaud S; Zapiola I; Fernandez Giuliano S; Bologna R; Mangano A; Aulicino PC
    J Antimicrob Chemother; 2020 Jun; 75(6):1567-1574. PubMed ID: 32125378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in Taiwan.
    Lai CC; Liu WC; Fang CT; Yang JY; Chang LH; Wu PY; Luo YZ; Chang SF; Su YC; Chang SY; Hung CC
    J Antimicrob Chemother; 2016 Jan; 71(1):226-34. PubMed ID: 26404079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analyses of HIV-1 integrase gene sequences among treatment-naive patients in the Eastern Cape, South Africa.
    Onoriode Digban T; Chucks Iweriebor B; Chikwelu Obi L; Nwodo U; Ifeanyi Okoh A
    J Med Virol; 2020 Aug; 92(8):1165-1172. PubMed ID: 31889319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance.
    Tschochner M; Chopra A; Maiden TM; Ahmad IF; James I; Furrer H; Günthard HF; Mallal S; Rauch A; John M
    Antivir Ther; 2009; 14(7):953-64. PubMed ID: 19918099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.